Suvretta Capital Management »

Eli Lilly & Co. shares owned by Suvretta Capital Management

Quarter-by-quarter ownership of Eli Lilly & Co. (LLY) shares owned by Suvretta Capital Management from 13F filings

Historical chart of Suvretta Capital Management investment in Eli Lilly & Co.

Tip: Access up to 7 years of quarterly data

All positions including Eli Lilly & Co. held by Suvretta Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Eli Lilly & Co. by Suvretta Capital Management

Quarter filed Position value Share count Share price at filing
2023-09-30 $21M 39k 537.13
2022-09-30 $11M 35k 323.35

More positions owned by Suvretta Capital Management

Royalty Pharma Shs Class A (RPRX)
Biohaven (BHVN)
Arcellx Common Stock (ACLX)
Horizon Therapeutics Pub L SHS
Insmed Com Par $.01 (INSM)
Meta Platforms Cl A (META)
Amazon (AMZN)
Advanced Micro Devices (AMD)
Intra Cellular Therapies (ITCI)
Microsoft Corporation (MSFT)
Kura Oncology (KURA)
Wynn Resorts (WYNN)
Marinus Pharmaceuticals Com New (MRNS)
89bio (ETNB)
General Electric Com New (GE)

View all positions for Suvretta Capital Management

Top funds holding Eli Lilly & Co.

Lilly Endowment
Vanguard Group
Pnc Financial Services
PRIMECAP Management Company
T. Rowe Price Associates
Jpmorgan Chase & Co
State Farm Mutual Automobile Insurance Company
Wellington Management Company
Bank of America Corporation
Norges Bank Investment Management
Jennison Associates
Legal & General Group
Bank of New York Mellon
Alliancebernstein
Goldman Sachs Group

View all funds holding Eli Lilly & Co.